Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Cros

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
Molecular Pharmacology|January 1, 1988
The biooxidation of cytotoxic ellipticine derivatives: a key to structure-activity relationship studies?G Meunier, D De Montauzon, J Bernadou, et al.
Journal of Medicinal Chemistry|December 1, 1983
Heterocyclic Quinones. 4. A new highly cytotoxic drug: 6,7-bis(1-aziridinyl)-5,8-quinazolinedioneJ Renault, S Giorgi-Renault, M Baron, et al.
Journal of Medicinal Chemistry|October 1, 1989
Cytostatic trans-platinum(II) complexesN Farrell, T T Ha, J P Souchard, et al.
Cancer Research|December 15, 1996
Transgenic mice expressing the Sh ble bleomycin resistance gene are protected against bleomycin-induced pulmonary fibrosisJ Weinbach, A Camus, J Barra, et al.
Journal of Medicinal Chemistry|August 1, 1986
Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(t)ides. Biological activities of the resulting adductsG Pratviel, J Bernadou, T Ha, et al.
Chemical & Pharmaceutical Bulletin|October 1, 1988
Heterocyclic quinones. XIII. Dimerization in the series of 5,8-quinazolinediones: synthesis and antitumor effects of bis(4-amino-5,8-quinazolinediones)S Giorgi-Renault, J Renault, M Baron, et al.
Diabetes & Metabolism|December 19, 2000
Managing type 2 diabetes in France: the ECODIA surveyB Detournay, S Cros, B Charbonnel, et al.
The Journal of Pharmacy and Pharmacology|August 1, 1984
Fluosol 43 intravascular persistence in mice measured by 19F nmrM C Malet-Martino, D Betbeder, A Lattes, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia modelS Cros, N Guilbaud, M Berlion, et al.
Neurorehabilitation and Neural Repair|February 21, 2009
Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticityD Bensmail, A B Ward, J Wissel, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
Molecular Pharmacology|January 1, 1988
The biooxidation of cytotoxic ellipticine derivatives: a key to structure-activity relationship studies?G Meunier, D De Montauzon, J Bernadou, et al.
Journal of Medicinal Chemistry|December 1, 1983
Heterocyclic Quinones. 4. A new highly cytotoxic drug: 6,7-bis(1-aziridinyl)-5,8-quinazolinedioneJ Renault, S Giorgi-Renault, M Baron, et al.
Journal of Medicinal Chemistry|October 1, 1989
Cytostatic trans-platinum(II) complexesN Farrell, T T Ha, J P Souchard, et al.
Cancer Research|December 15, 1996
Transgenic mice expressing the Sh ble bleomycin resistance gene are protected against bleomycin-induced pulmonary fibrosisJ Weinbach, A Camus, J Barra, et al.
Journal of Medicinal Chemistry|August 1, 1986
Ribose as the preferential target for the oxidized form of elliptinium acetate in ribonucleos(t)ides. Biological activities of the resulting adductsG Pratviel, J Bernadou, T Ha, et al.
Chemical & Pharmaceutical Bulletin|October 1, 1988
Heterocyclic quinones. XIII. Dimerization in the series of 5,8-quinazolinediones: synthesis and antitumor effects of bis(4-amino-5,8-quinazolinediones)S Giorgi-Renault, J Renault, M Baron, et al.
Diabetes & Metabolism|December 19, 2000
Managing type 2 diabetes in France: the ECODIA surveyB Detournay, S Cros, B Charbonnel, et al.
The Journal of Pharmacy and Pharmacology|August 1, 1984
Fluosol 43 intravascular persistence in mice measured by 19F nmrM C Malet-Martino, D Betbeder, A Lattes, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia modelS Cros, N Guilbaud, M Berlion, et al.
Neurorehabilitation and Neural Repair|February 21, 2009
Cost-effectiveness modeling of intrathecal baclofen therapy versus other interventions for disabling spasticityD Bensmail, A B Ward, J Wissel, et al.
Pageof 6